AbbVie’s ASCO 2025 ADC breakthroughs: Transforming oncology with Temab-A ABBV-706 & PVEK

AbbVie presented new data from its novel antibody-drug conjugates (ADCs) at ASCO 2025, including telisotuzumab adizutecan (Temab-A) in advanced non-small cell lung cancer, ABBV-706 in high-grade neuroendocrine neoplasms (NENs), and pivekimab sunirine (PVEK) in blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Onsite in Chicago, web editor Nicole Raleigh spoke with Daejin Abidoye, MD, Head of Solid Tumors, Oncology Development at AbbVie about that fresh data, as well as the practice-changing potential of ADCs as an emerging oncological therapy.

They also discussed the company’s recent work with patient advocacy, a multi-year collaboration with the Chicago Cubs recently announced.

Watch this and other conversations at ASCO 2025 here.